Skip to content

Effect of transcutaneous electrical stimulation on the dose-effect relationship of sufentanil in suppressing the stress response in frail patients undergoing visual double-lumen endobronchial tubes

Effect of transcutaneous electrical stimulation on the dose-effect relationship of sufentanil in suppressing the stress response in frail patients undergoing visual double-lumen endobronchial tubes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082443
Enrollment
Unknown
Registered
2024-03-29
Start date
2023-03-27
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress response to tracheal intubation

Interventions

Control Group:TCL Sufentanil
TEAS Group:TCL Sufentanil + Continuous electrical stimulation of Neiguan and Hegu points for 30 minutes before induction
Sham Group:TCL Sufentanil + Only attach electrode pads

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Chinese Traditional Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for VATS lung surgery with VDLT intubation and general anesthesia; 2. Frail patients (FRAIL scale =3 points); 3. The patient’s age is =65 years old and =75 years old; 4. Those who sign the informed consent form; 5. Relevant auxiliary examinations have been completed, such as blood routine, lung function, liver and kidney function, bleeding and coagulation function, etc.

Exclusion criteria

Exclusion criteria: 1. There are drug abusers; 2. The surgical plan is temporarily changed to thoracotomy or bilateral surgery; 3. Patients who are allergic to amide local anesthetics or DET or DEM; 4. Preoperative basal heart rate is lower than 50bpm; 5. Patients with cognitive dysfunction, language impairment, and poor ability to understand scales; 6. Patients with confirmed mental illness; 7. Patients who have had a history of acupuncture treatment; 8. Patients with New York Heart Association (NYHA) cardiac function class III-IV; 9. Patients with Canadian Cardiovascular Society (CCS) coronary heart disease classification III-IV; 10. Patients with end-stage liver disease or end-stage renal disease (glomerular filtration rate GFR <15ml/min)

Design outcomes

Primary

MeasureTime frame
Sufentanil EC95;

Secondary

MeasureTime frame
Sufentanil EC50;blood pressure;heart rate;bispectral index;catecholamine;steroid;Airway score;Sufentanil dosage;Propofol dosage;postoperative nausea and vomiting;throat irritation;rescue analgesic medication and dosage for the last 24 hours;First time out of bed activity time and amount of exercise;saturation of pulse oximetry;

Countries

China

Contacts

Public ContactXu Hua

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Chinese Traditional Medicine

pshhuaxu@163.com+86 138 1689 5738

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026